Theravance Biopharma (TBPH) Profit After Tax (2013 - 2026)

Theravance Biopharma (TBPH) has reported Profit After Tax for 14 consecutive years, with -$4.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax rose 63.67% year-over-year to -$4.9 million; the TTM figure through Mar 2026 stood at $114.5 million (up 296.36% YoY), while the FY2025 annual figure was $105.9 million, up 287.7% from the prior year.
• Profit After Tax fell to -$4.9 million in Q1 2026 per TBPH's latest filing, from $61.0 million in the prior quarter.
• Across five years, Profit After Tax topped out at $916.6 million in Q3 2022 and bottomed at -$41.5 million in Q1 2022.
• Historically, Profit After Tax has averaged $48.4 million across 5 years, with a median of -$12.7 million in 2024.
• Annual changes were most pronounced in 2022 — Profit After Tax soared 2696.1% — and 2023, when it sank 100.98%.
• Theravance Biopharma's Profit After Tax stood at -$14.3 million in 2022, then soared by 40.31% to -$8.5 million in 2023, then slumped by 82.46% to -$15.5 million in 2024, then surged by 493.02% to $61.0 million in 2025, then sank by 108.08% to -$4.9 million in 2026.
• Business Quant data shows TBPH's Profit After Tax at -$4.9 million in Q1 2026, $61.0 million in Q4 2025, and $3.6 million in Q3 2025.